Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Genentech |
---|---|
Information provided by: | Genentech |
ClinicalTrials.gov Identifier: | NCT00096980 |
This study is an open label, randomized, multicenter study designed to compare the efficacy of 12 weeks of subcutaneously administered efalizumab (monotherapy) with that of combination therapy (Efalizumab and a topical corticosteroid ointment) in subjects with moderate to severe plaque psoriasis who are candidates for systemic therapy. The study will also evaluate the safety and tolerability of 30 months of continuous efalizumab treatment in those subjects who derive benefit from the initial 12 weeks of treatment.
Condition | Intervention | Phase |
---|---|---|
Psoriasis |
Drug: Raptiva (efalizumab) |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Safety/Efficacy Study |
Official Title: | An Open Label, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneously Administered Efalizumab Used in Combination With Topical Psoriasis Therapies for Prolonged Maintenance Treatment |
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | ACD2243g |
Study First Received: | November 17, 2004 |
Last Updated: | April 26, 2006 |
ClinicalTrials.gov Identifier: | NCT00096980 |
Health Authority: | United States: Food and Drug Administration |
Skin Diseases Psoriasis Skin Diseases, Papulosquamous |